CRISPR Therapeutics director sells shares worth $780,935
Ali Behbahani, a CRISPR Therapeutics director, reported a direct sale of common shares on 2026-09-17 at a weighted average price of $57.0901 per share, totaling $780,935.
Ali Behbahani, a CRISPR Therapeutics director, reported a direct sale of common shares on 2026-09-17 at a weighted average price of $57.0901 per share, totaling $780,935.